A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Trial Details

NCT ID

NCT07284849

Phase

PHASE3

Sponsor

Incyte Corporation

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

• INCA33890
• Placebo
• Bevacizumab
• FOLFOX

Locations (sample)

• Mobile, Alabama, United States|30.69436,-88.04305
• Tucson, Arizona, United States|32.22174,-110.92648
• Tucson, Arizona, United States|32.22174,-110.92648
• Fountain Valley, California, United States|33.70918,-117.95367
• Fullerton, California, United States|33.87029,-117.92534

Key Eligibility Criteria

• Stage IV colorectal adenocarcinoma not amenable to curative resection.
• No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there w…
• Measurable disease per RECIST v1.1.
• ECOG performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.